[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].

about

[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].

Item

http://www.wikidata.org/entity/Q40797796

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

[Cardiovascular risk of androg ...... ntagonists and GnRH agonists].

@en

type

Item

label

[Cardiovascular risk of androg ...... ntagonists and GnRH agonists].

@en

prefLabel

[Cardiovascular risk of androg ...... ntagonists and GnRH agonists].

@en

P1476

[Cardiovascular risk of androg ...... antagonists and GnRH agonists]

@en

P2093

B Kherad

http://www.w3.org/2001/XMLSchema#string

B Pieske

http://www.w3.org/2001/XMLSchema#string

C A Schneider

http://www.w3.org/2001/XMLSchema#string

C Tschöpe

http://www.w3.org/2001/XMLSchema#string

F Krackhardt

http://www.w3.org/2001/XMLSchema#string

P2860

The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance

Testosterone and the cardiovascular system: a comprehensive review of the basic science literature

Expression of follicle-stimulating hormone receptor in tumor blood vessels

Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action.

Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation.

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer

P304

697-705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S00059-016-4422-8

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Frank Spillmann

P577

2016-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27083586

http://www.w3.org/2001/XMLSchema#string